Lantheus Holdings, Inc.

LNTH • Drug Manufacturers - Specialty & Generic

$100.97

▼ -0.01 (-0.01%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL MUY FAVORABLEExcelenteConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Alta calidad del negocio, con crecimiento y flujo de caja que respaldan el caso. La valoración todavía importa, pero el historial de ratios es favorable.

Capitalización

$6.82B

Crecimiento

1.0%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 15.2%Crecimiento positivo de ingresos · 38.0%Flujo de caja libre positivo · 5.25Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 19.23

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 12:39 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$100.97

Change-0.01%

Shares Out67.52M

Market Cap$6.82B

Enterprise Value$6.80B

52W Range49.67 - 111.86

Beta-0.06

P/E24.76

P/S4.38

P/B5.20

P/FCF13.52

EV/Sales4.37

Price$100.97

Change-0.01%

Shares Out67.52M

Market Cap$6.82B

Enterprise Value$6.80B

52W Range49.67 - 111.86

Beta-0.06

P/E24.76

P/S4.38

P/B5.20

P/FCF13.52

EV/Sales4.37

EV/EBITDA14.60

EV/FCF13.47

Earnings Yield4.04%

FCF Yield7.40%

Dividend Yield0.00%

Gross Margin61.10%

Oper. Margin20.16%

Profit Margin15.15%

Debt/Eq0.57

Current Ratio2.70

Quick Ratio2.51

Revenue 5Y1.04%

FCF 5Y13.78%

Target$105.27

Target Upside4.26%

Target Median$102.50

Target Range94.00 - 120.00

Volume2.23M

Avg Volume972.50K

EPS Surprise0.21

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

83/100

Fortaleza financiera

Deuda, caja, estabilidad

92/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

76/100

Por qué este puntaje▼

Márgenes estables o en mejora · 15.2%Crecimiento positivo de ingresos · 38.0%Flujo de caja libre positivo · 5.25Flujo de caja libre consistente · 5/5Múltiplo de ganancias razonable · 19.23Nivel de deuda manejable · 0.57

Analyst view

Analyst sentiment and price target

LNTH

Analyst sentiment

Based on 19 analyst votes · 2026-09-05

79/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$94.00

Promedio

$105.25

Mediana

$102.50

Alto

$120.00

Resumen de la compañía

IPO: 6/25/2015

Industria: Drug Manufacturers - Specialty & Generic

P/B i: 5.20

Deuda / Patrimonio i: 0.57

Margen operativo: 20.16%

Margen neto: 15.15%

ROE i: -

ROIC: -

Salud financiera

Puntaje18 / 20

Deuda / Patrimonio: 0.57

Ratio corriente: 2.70

Ratio rápido: 2.51

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

EASTLAND JULIA MARIE

Transacción: 05/14/2026

COMPRA

Cambio

+4,137

Precio

Not reported

Presentación

05/18/2026

Tipo

COMPRA

Thrall James H

Transacción: 05/14/2026

COMPRA

Cambio

+4,137

Precio

Not reported

Presentación

05/18/2026

Tipo

COMPRA

Ber Gerard

Transacción: 05/14/2026

COMPRA

Cambio

+4,137

Precio

Not reported

Presentación

05/18/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
EASTLAND JULIA MARIE	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
Thrall James H	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
Ber Gerard	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
Baylor-Henry Minnie	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
Pruden Gary J	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
LENO SAM R	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
Maeusli Heinz Christoph	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
Morrow Phuong Khanh	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
McHugh Julie	COMPRA	+4,137	Not reported	05/14/2026	05/18/2026
Niedzwiecki Daniel	VENTA	-1,911	$83.82	04/17/2026	04/21/2026
Morgan Amanda Michelle	VENTA	-595	$76.31	03/05/2026	03/09/2026
Brown Kimberly	VENTA	-133	$76.31	03/05/2026	03/09/2026
Marshall Robert J. Jr.	VENTA	-1,182	$76.31	03/05/2026	03/09/2026
Dinkelborg Ludger	COMPRA	+20,966	Not reported	03/05/2026	03/09/2026
Niedzwiecki Daniel	VENTA	-1,283	$76.31	03/05/2026	03/09/2026
Heino Mary Anne	VENTA	-41,916	$76.30	03/02/2026	03/04/2026
Marshall Robert J. Jr.	VENTA	-10,652	$76.30	03/02/2026	03/04/2026
Morgan Amanda Michelle	VENTA	-3,336	$76.30	03/02/2026	03/04/2026
Niedzwiecki Daniel	VENTA	-8,259	$76.30	03/02/2026	03/04/2026
Morgan Amanda Michelle	VENTA	-368	$66.57	12/15/2025	12/17/2025

Sobre la compañía

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

Fuente - Link

Competidores

ACAD ADMA AMRX BHC CRNX HCM HNGE INDV PRAX SUPN

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per sha

GuruFocus

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus' products through 2030.Halper Sadeh encourages Lantheus shareholders to click here to learn more about their.

Business Wire

US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

The U.S. Food and Drug Administration has approved a radioactive agent from ‌Lantheus Holdings for use in brain scans to help assess patients for Alzheimer's disease, the company said on Friday.

Reuters

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer's Disease

BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease to identify patients with tau neurofibrillary tangle (NFT) pathology. TAUKLARIFY has a limitation of use. The safety and effectiveness of TAUKLARIFY have not been established for the evaluation of non-Alzheimer's disease tauopathies.

GlobeNewsWire

Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?

Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 7, 2026

GuruFocus

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	1.25	1.46	0.21
2026-02-26	1.18	1.67	0.49
2025-11-06	1.27	1.27	0
2025-08-06	1.64	1.57	-0.07
2025-05-07	1.68	1.53	-0.15
2025-02-26	1.58	1.59	0.01
2024-11-06	1.56	1.7	0.14
2024-07-31	1.83	1.8	-0.03
2024-05-02	1.54	1.69	0.15
2024-02-22	1.45	1.75	0.3
2023-11-02	1.32	1.47	0.15
2023-08-03	1.31	1.54	0.23